This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv™Rx device is pending Premarket Approval from the U.S. FDA, and if granted, will become the first FDA-cleared medical device for MDD treatment that can be delivered outside of the clinic BURLINGTON, Mass. and JERUSALEM, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a glob ...

Core Insights - BrainsWay Ltd. achieved record quarterly sales of $11.4 million in Q4 2024, marking a 27% increase compared to Q4 2023 [1][4] - The full year 2024 revenue rose nearly 30% year-over-year to $41 million [1][4] - The company exceeded its full year 2024 operating income and Adjusted EBITDA margin guidance [1] - For 2025, BrainsWay expects continued strong growth, projecting revenue between $49 million and $51 million, indicating a growth of 20% to 24% over 2024 [1][10] Q4 2024 Financial Highlights - Q4 2024 revenue was $11.4 million, a 27% increase from Q4 2023 [4] - A total of 75 Deep TMS™ systems were shipped, a 25% increase from the previous year [4] - Gross margin for Q4 2024 remained at 75%, consistent with the prior year [4] - Operating income for Q4 2024 was $0.4 million, up from $0.2 million in Q4 2023 [4] - Adjusted EBITDA for Q4 2024 was approximately $1.4 million, compared to $0.8 million in Q4 2023 [4] - Net income for Q4 2024 was $1.5 million, significantly higher than $0.1 million in Q4 2023 [4] Full Year 2024 Financial Highlights - Full year 2024 revenue reached $41 million, a 29% increase from 2023 [4] - Gross margin for the full year was 75%, slightly up from 74% in the previous year [4] - Operating income for the full year was $1.4 million, a turnaround from a loss of $5 million in 2023 [4] - Net income for the full year was $2.9 million, compared to a net loss of $4.2 million in 2023 [4] - Adjusted EBITDA for the full year was approximately $4.5 million, compared to an adjusted EBITDA loss of $2.4 million in the prior year [4] Strategic Developments - The company completed a $20 million strategic equity financing transaction with Valor Equity Partners [4] - As of December 31, 2024, cash and cash equivalents totaled $69.4 million, a significant increase from $10.5 million in 2023 [4][19] - BrainsWay received expanded FDA labeling for Deep TMS to treat late-life depression, broadening the age range for treatment [4] - The company reported a significant increase in Deep TMS treatments for anxious depression in the second half of 2024, addressing a large medical condition affecting millions in the U.S. [4] 2025 Financial Guidance - BrainsWay anticipates revenue for 2025 to be between $49 million and $51 million, representing a growth of 20% to 24% over 2024 [10] - The company targets an operating income of 3% to 4% and an Adjusted EBITDA of 11% to 12% for the full year 2025 [10]